CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026

Core Insights - CytoSorbents Corporation has launched HotSwap™, a new system designed to enhance the efficiency of blood purification therapy for critically ill patients, allowing for rapid and safe device exchanges during treatment [1][3][5] - The company has renewed its strategic partnership with Aferetica Srl in Italy, which has been instrumental in the adoption of CytoSorb technology in critical care and organ transplantation [2][3] - New clinical data presented at ISICEM 2026 supports the efficacy of CytoSorb therapy across various critical illnesses, reinforcing its role as a frontline treatment [4][5] Product Launch - HotSwap™ enables seamless exchange of CytoSorb adsorbers, improving treatment timing and reducing the workload on ICU staff [1][3] - The system facilitates the safe return of blood from used devices back to patients, which is crucial for maintaining blood volume during treatment [3] Partnership Renewal - The renewed agreement with Aferetica Srl extends a successful collaboration that has lasted over a decade, focusing on blood purification and organ preservation [2] - Both companies aim to continue expanding their innovations in blood purification and organ transplantation [2] Clinical Evidence - New clinical data presented at ISICEM includes findings from the COSMOS Registry, a Rhabdomyolysis Substudy, and a Meta-Analysis in COVID-19, highlighting the effectiveness of CytoSorb therapy [4][5] - Key outcomes from studies indicate significant improvements in patient survival rates and reductions in inflammatory markers, supporting the therapy's versatility in critical care [6][5]